Research programme: Cancer Therapies - iCell Therapeutics
Alternative Names: LDE-TTXLatest Information Update: 16 Jul 2016
At a glance
- Originator iCell Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Canada
- 13 Oct 2005 Preclinical trials in Cancer in Canada (unspecified route)